Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2016 1
2017 2
2018 1
2020 2
2021 4
2022 12
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project.
Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, Provenzano L, Mazzeo L, Dumitrascu AD, Sonnek J, Szewczyk M, Watermann I, Trovò F, Dollis N, Sarris E, Garassino MC, Bestvina CM, Pedrocchi A, Ambrosini E, Kosta S, Felip E, Soleda M, Roca AA, Rodríguez-Morató J, Nuara A, Lourie Y, Fernandez-Pinto M, Aguaron A, Pravettoni G. Sebri V, et al. Among authors: bestvina cm. Cancer Med. 2024 May;13(9):e7159. doi: 10.1002/cam4.7159. Cancer Med. 2024. PMID: 38741546 Free PMC article. Review.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, Viscardi G, Ferrara R, Veronesi G, Forde PM, Taube J, Vokes E, Bestvina CM, Dolezal JM, Sacco M, Monteforte M, Cascone T, Garassino MC, Torri V. Hines JB, et al. Among authors: bestvina cm. J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117-5. doi: 10.1016/j.jtho.2024.03.010. Online ahead of print. J Thorac Oncol. 2024. PMID: 38461929 Free article.
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Lefebvre P, He A, Vanderpoel J. Bestvina CM, et al. J Med Econ. 2024 Jan-Dec;27(1):292-303. doi: 10.1080/13696998.2024.2314430. Epub 2024 Feb 24. J Med Econ. 2024. PMID: 38391239 Free article.
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
Beckermann KE, Bestvina CM, El Osta B, Sanborn RE, Borghaei H, Lammers PE, Selvaggi G, Whisenant JG, Heimann-Nichols E, Berry L, Hsu CY, Shyr Y, Horn L, Wakelee H. Beckermann KE, et al. Among authors: bestvina cm. JTO Clin Res Rep. 2023 Dec 15;5(2):100619. doi: 10.1016/j.jtocrr.2023.100619. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38328473 Free PMC article.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.
Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Kuboki Y, et al. Among authors: bestvina cm. Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4. Nat Med. 2024. PMID: 38177853 Clinical Trial.
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Burns L, et al. Among authors: bestvina cm. Lung Cancer. 2023 Dec;186:107423. doi: 10.1016/j.lungcan.2023.107423. Epub 2023 Nov 13. Lung Cancer. 2023. PMID: 37995456 Free article.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Cameron RB, Hines JB, Torri V, Porcu L, Donington J, Bestvina CM, Vokes E, Dolezal JM, Esposito A, Garassino MC. Cameron RB, et al. Among authors: bestvina cm. Ther Adv Med Oncol. 2023 Sep 15;15:17588359231198446. doi: 10.1177/17588359231198446. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37720499 Free PMC article. Review.
42 results